Cyclerion Therapeutics (CYCN) EBIAT (2019 - 2025)
Cyclerion Therapeutics (CYCN) has 7 years of EBIAT data on record, last reported at -$976000.0 in Q3 2025.
- For Q3 2025, EBIAT fell 34.99% year-over-year to -$976000.0; the TTM value through Sep 2025 reached -$2.2 million, up 58.62%, while the annual FY2024 figure was -$3.6 million, 71.99% up from the prior year.
- EBIAT reached -$976000.0 in Q3 2025 per CYCN's latest filing, down from -$324000.0 in the prior quarter.
- Across five years, EBIAT topped out at $12.4 million in Q4 2022 and bottomed at -$16.2 million in Q2 2021.
- Average EBIAT over 5 years is -$3.9 million, with a median of -$1.8 million recorded in 2023.
- The widest YoY moves for EBIAT: up 271.68% in 2023, down 114.48% in 2023.
- A 5-year view of EBIAT shows it stood at -$10.8 million in 2021, then skyrocketed by 215.03% to $12.4 million in 2022, then crashed by 114.48% to -$1.8 million in 2023, then skyrocketed by 127.97% to $502000.0 in 2024, then crashed by 294.42% to -$976000.0 in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were -$976000.0 in Q3 2025, -$324000.0 in Q2 2025, and -$1.4 million in Q1 2025.